AMRX Stock Recent News

Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Does Amneal Pharmaceuticals (AMRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here is how Amneal Pharmaceuticals (AMRX) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Amneal (AMRX) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Amneal Pharmaceuticals has seen a significant increase in its share price of >400% after hitting an all-time low in March 2023. The company reported record revenues in Q1 2024, with growth in all three reportable segments - Generics, Specialty, and AvKare. Amneal is projecting new product launches and international expansion to add multi-billions of dollars of revenues by 2027, and profitability - on an adjusted basis at least - is in evidence.

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced the launch of FOCINVEZ™, a ready-to-use injectable. Unlike other versions of fosaprepitant, this single-dose vial product is free of Polysorbate 80 and does not require reconstitution or dilution and can be administered directly from the vial using the included vial hanger. FOCINVEZ for injection is indicated in adults and pediatric patients 6 months of age and older, in c.

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the continued expansion of its injectables portfolio with six new injectable product launches during the second quarter of 2024, bringing the Company's total number of commercial injectable products available for the U.S. institutional market to over 40. The growth of Amneal's broad injectables portfolio will help address shortages of critical products where there may be l.

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California.

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Participate at Upcoming Investor Conference.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q1 2024 Results Earnings Conference Call May 3, 2024 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President and Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Executive Vice President and Chief Financial Officer Joe Renda - Senior Vice President, Chief Commercial Officer, Specialty Conference Call Participants Nathan Rich - Goldman Sachs Leszek Sulewski - Truist Securities David Amsellem - Piper Sandler Balaji Prasad - Barclays Capital Chris Schott - J.P. Morgan Operator Good morning and welcome to Amneal Pharmaceuticals First Quarter 2024 Earnings Call.